- Supported exchanges /
- TWO /
- 4157.TWO
Taigen Biopharmaceuticals Holdings Ltd (4157 TWO) stock market data APIs
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.
Taigen Biopharmaceuticals Holdings Ltd Financial Data Overview
| 14.15 | |
| 14.15 | |
| - | |
| 14.25 | |
| 14.1 | |
| 13.05-17.25 | |
| 10 157 M | |
| 42.8788 | |
| 718 M | |
| 149 M | |
| -0.16 | |
| 0.764 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Taigen Biopharmaceuticals Holdings Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 149 M
- EBITDA -149 564 000
- Earnings Per Share 0.33
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Taigen Biopharmaceuticals Holdings Ltd Earnings via APIs
- Latest Release 2023-03-09
- EPS/Forecast NaN
Get Taigen Biopharmaceuticals Holdings Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
